PKPD modeller. - Currently responsible for the modelling of preclinical and early clinical PK, biomarker, efficacy and safety data focussed on Respiratory drug development. -Role involves experimental design, optimisation and modelling of clinical studies plus dose projection to man. -Wide range of additional drug discovery experience in both biology and DMPK fields including regulatory interaction supporting late stage DMPK strategy. Specialities: -Expertise in NONMEM, R, and Berkeley Madonna -Familiar with Gastroplus, Monolix and SimCYP

Director Clinical Pharmacology Modelling and Simulation @ • Preparation and implementation of model based development strategies Discovery and Development • Integration of clinical PK and PK/PD into clinical development plans • Clinical PK, PK/PD, population PK/PD and M&S contribution to all programs, where appropriate • Developing and/or maintaining an advanced knowledge of pharmacology, biology,therapeutics, drug metabolism, bioanalysis, and biopharmaceutics such that the benefit of CPMS principles can be fully exploited From June 2014 to Present (1 year 7 months) PKPD modeller. (Senior Clinical Pharmacokinetisist). Clinical Pharmacology and DMPK group @ PKPD modeller. From June 2011 to June 2014 (3 years 1 month) Cambridge, United KingdomPKPD modeller Senior Principal Scientist @ From January 2007 to May 2011 (4 years 5 months) Principal Scientist @ Lead project representative for Pharmacokinetics, Dynamics and Metabolism department. From January 2004 to January 2007 (3 years 1 month) Senior Scientist @ Research associate to senior scientist - cardiovascular biology. From September 1991 to January 2004 (12 years 5 months)

MSc, Modelling and Simulation in PKPD @ The University of Manchester From 2009 to 2011 BSc Hons, Pharmacology @ Open University From 1991 to 1996 David Fairman is skilled in: Drug Metabolism, Pharmacokinetics, Clinical Pharmacology, DMPK, Pharmacodynamics, ADME, Clinical Development, NONMEM, Translational Medicine, IND, Translational Research, GLP, PK/PD, Monoclonal Antibodies, Biomarkers